Drug Trial Radar · NCT03312556
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 21, 2017
Primary completion
Dec 21, 2026
Study completion Jan 21, 2027
Sponsor
- Lead sponsor
- Vanderbilt University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 17, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.
Conditions
- Supine Hypertension
- Autonomic Failure
Interventions
continuous positive airway pressure (CPAP)Device
Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
PlaceboDrug
Placebo pill or patch. Single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Supine Systolic Blood PressureTime frame: 12 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Autonomic Dysfunction Center/ Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.